| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Cyp3a13 |
| Uniprot No | Q64464 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-503aa |
| 氨基酸序列 | MDLIPNFSMETWMLLATSLVLLYLYGTHSHGIFKKLGIPGPKPLPFLGTILAYQKGFWECDIQCHKKYGKMWGLYDGRQPVLAITDPDIIKTVLVKECYSTFTNRRRFGPVGILKKAISISENEEWKRIRALLSPTFTSGRLKEMFPIINQFTDVLVRNMRQGLGEGKPTSMKDIFGAYSMDVITATSFGVNIDSLNNPQDPFVEKIKKLLKFDIFDPLFLSVTLFPFLTPVFDALNVSLFPRDVISFFTTSVERMKENRMKEKEKQRVDFLQLMINSQNYKTKESHKALSDVEIVAQSVIFIFAGYETTSSALSFALYLLAIHPDVQKKLQDEIDAALPNKAPATYDTLLQMEYLDMVVNETLRLYPIAGRLERVCKTDVEINGLFIPKGTVVMIPTFALHKDPKYWPEPEEFRPERFSKKNQDSINPYMYLPFGSGPRNCIGMRFALINMKVALVRVLQNFTVQPCKETEIPLKLSKQGLLQPENPLLLKVVSRDETVSDE |
| 预测分子量 | 73.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Cyp3a13重组蛋白的3篇参考文献概览，涵盖其功能、表达及调控研究：
---
1. **文献名称**：*"Characterization of recombinant cytochrome P450 3A13: Role in xenobiotic metabolism"*
**作者**：Zhang H, et al.
**摘要**：该研究通过在大肠杆菌中重组表达小鼠Cyp3a13蛋白，分析其代谢活性和底物特异性。发现Cyp3a13对黄曲霉毒素B1等致癌物具有显著催化活性，提示其在毒物代谢中的作用可能与人类CYP3A4存在差异。
2. **文献名称**：*"Tissue-specific expression and inducibility of CYP3A13 in mice: Implications for drug interactions"*
**作者**：Li Y, Wang L, et al.
**摘要**：研究利用重组Cyp3a13蛋白探讨其在小鼠肝脏和肠道中的诱导表达机制。发现其受孕烷X受体(PXR)调控，且与Cyp3a11协同参与药物代谢，为小鼠模型中药物-药物相互作用研究提供依据。
3. **文献名称**：*"Functional comparison of CYP3A13 and CYP3A4 in the metabolism of tyrosine kinase inhibitors"*
**作者**：Guo J, et al.
**摘要**：通过昆虫细胞表达系统制备重组Cyp3a13和CYP3A4蛋白，对比两者对伊马替尼等靶向药物的代谢能力。结果显示Cyp3a13的催化效率较低，但底物结合亲和力与人类同源物相似，提示小鼠模型用于药物筛选时需谨慎解读数据。
---
**注**：以上文献为虚拟示例，实际研究需通过PubMed/SciHub等平台检索具体论文。建议结合关键词“Cyp3a13 recombinant protein expression/metabolism/kinetics”进一步筛选近年文献。
CYP3A13. a member of the cytochrome P450 3A subfamily, is a drug-metabolizing enzyme primarily studied in preclinical models, particularly mice. While humans predominantly express CYP3A4 and CYP3A5 in the liver and gut, CYP3A13 exhibits species-specific expression patterns. In mice, it is found in extrahepatic tissues like the lung, kidney, and gastrointestinal tract, suggesting a role in local xenobiotic metabolism. This enzyme participates in Phase I metabolism, catalyzing oxidation reactions to facilitate the elimination of drugs, toxins, and endogenous compounds.
Recombinant CYP3A13 protein is engineered using heterologous expression systems (e.g., E. coli, baculovirus-insect cell systems) to produce purified enzyme for functional studies. Its recombinant form enables researchers to investigate substrate specificity, catalytic activity, and interactions with drugs or inhibitors without interference from other metabolic enzymes. This is critical for deciphering its unique metabolic profile compared to other CYP3A isoforms.
Studies on recombinant CYP3A13 have revealed insights into interspecies metabolic differences, aiding the translation of preclinical findings to human applications. It also helps assess drug-drug interaction risks and tissue-specific toxicity mechanisms. Despite lower hepatic abundance, its role in extrahepatic metabolism may influence drug efficacy and safety in target tissues. However, its physiological relevance remains less characterized than human CYP3A enzymes, prompting ongoing research to clarify its contributions to systemic and local pharmacokinetics. Recombinant CYP3A13 serves as a valuable tool for optimizing drug candidates and understanding species-dependent metabolic pathways.
×
